QED Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- QED Therapeutics's estimated annual revenue is currently $3.4M per year.
- QED Therapeutics received $65.0M in venture funding in January 2018.
- QED Therapeutics's estimated revenue per employee is $77,500
- QED Therapeutics's total funding is $65M.
Employee Data
- QED Therapeutics has 44 Employees.
- QED Therapeutics grew their employee count by 0% last year.
QED Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is QED Therapeutics?
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
keywords:N/A
$65M
Total Funding
44
Number of Employees
$3.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
QED Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Regulatory Affairs Manager | Reveal Email/Phone |
2 | Sr. Director Biostatistics | Reveal Email/Phone |
3 | Director, Clinical Operations | Reveal Email/Phone |
4 | Associate Director, Quality Assurance | Reveal Email/Phone |
5 | Associate Director Quality Assurance | Reveal Email/Phone |
6 | Director, Pharmaceutical Development | Reveal Email/Phone |
7 | Senior Clinical Program Manager | Reveal Email/Phone |
8 | Executive Director | Reveal Email/Phone |
9 | Associate Director Scientific Communications | Reveal Email/Phone |
10 | Executive Director Clinical Quality Assurance | Reveal Email/Phone |
QED Therapeutics News
... HER2 negative Breast Cancer treatment therapies, as per DelveInsight ... QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer,...
Sarepta Therapeutics is also focused on the disease. ... comes about a year after BridgeBio launched QED Therapeutics to develop infigratinib, ...
SAN FRANCISCO, June 3, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of data demonstrating the clinical ...
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of preclinical data demonstrating the ...
Other Companies in Palo Alto
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.8M | 44 | -15% | N/A |
#2 | $6.3M | 44 | -8% | N/A |
#3 | $5.4M | 44 | 159% | N/A |
#4 | $6.2M | 44 | 2% | N/A |
#5 | $6.8M | 44 | 52% | $10M |
QED Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-01-31 | $65.0M | Undisclosed | BridgeBio Pharma | Article |